Rictor is amplified in a subset of human cancers, such as lung and breast cancers, and is associated with cancer progression and therapeutic resistance. There is an association between RICTOR amplification and sensitivities to mTOR1/2 inhibitors in non-small cell lung cancer cells. Here, RICTOR is linked to breast carcinoma.